Sotatercept: First Approval
Drugs · 2024-07 · 84 (7) · 857-862
DOI: 10.1007/s40265-024-02058-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 21.06.2024. Verfasst von Connie Kang. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that is being developed by Merck and Co., Inc. (Rahway, NJ, USA) for the treatment of pulmonary arterial hypertension. Sotatercept recently received approval in the USA for the treatment of adults with pulmonary arterial hypertension [World Health Organisation (WHO) Group 1] to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events. This article summarizes the milestones in the development of sotatercept leading to this first approval for pulmonary arterial hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Kang, C. (2024). Sotatercept: First Approval. Drugs, 84(7), 857-862. https://doi.org/10.1007/s40265-024-02058-9
Vancouver
Kang C. Sotatercept: First Approval. Drugs. 2024;84(7):857-862. doi:10.1007/s40265-024-02058-9
BibTeX
@article{Kang2024,
author = {Kang, Connie},
title = {Sotatercept: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
number = {7},
pages = {857--862},
doi = {10.1007/s40265-024-02058-9}
}
EUVIMED